Ignite Creation Date:
2024-05-06 @ 2:11 AM
Last Modification Date:
2024-10-26 @ 11:14 AM
Study NCT ID:
NCT01982552
Status:
COMPLETED
Last Update Posted:
2018-02-05
First Post:
2013-11-06
Brief Title:
An Observational Study to Assess Patient Satisfaction and Control of Psoriasis With CalcipotrieneBetamethasone Dipropionate Taclonex Topical Suspension and Effect on Quality of Life
Sponsor:
LEO Pharma
Organization:
LEO Pharma
Study Overview
Official Title:
An Observational Study to Assess Patient Satisfaction and Control of Psoriasis With CalcipotrieneBetamethasone Dipropionate Taclonex Topical Suspension and Effect on Quality of Life
Status:
COMPLETED
Status Verified Date:
2018-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to document quality of life patient satisfaction effect on itching and control of psoriasis vulgaris associated with use of calcipotrienebetamethasone dipropionate Taclonex topical suspension 0005 0064 for treatment of plaque psoriasis under real-life conditions
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None